News
Dr. Vinay Prasad, a prominent critic of the pharmaceutical industry and the Food and Drug Administration, has been named to ...
A blanket requirement for placebo-controlled trials threatens research ethics and vaccine access, it’s being argued.
Novavax Inc. closed 73.72% short of its 52-week high of $23.86, which the company achieved on June 6th.
Novavax (NASDAQ:NVAX) has updated the terms of the previously announced collaboration and licensing agreement with Takeda (NYSE:TAK). The terms of the amended agreement for the development, ...
Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in ...
The FDA is expected to unpause the only protein-based COVID-19 vaccine's transition from emergency approval to full approval.
Have you ever wondered about what became of COVID vaccine companies after the pandemic settled down? Find out in this article ...
Some 20 travel staff at the FDA, who made arrangements for the regulator’s inspectors, will be getting their jobs back, as ...
If the FDA deems Pfizer’s and Moderna’s updated vaccines “new” products, it’s extremely unlikely the doses would be ready for ...
Shares of Novavax Inc. NVAX slipped 3.90% to $6.41 Thursday, on what proved to be an all-around great trading session for the ...
The US Department of Health and Human Services said Thursday that it aims to accomplish within four years a scientific feat ...
Additional data required by the FDA are the latest evidence of what one analyst described as a “higher bar” for vaccines.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results